Novartis Pharma AGrapcabtagene autoleucelcyclophosphamideDiffuse cutaneous systemic sclerosis (dcSSc)fludarabinedcSScCD19-targeted chimeric antigen receptor (CAR)-T cell therapy
…ry dcSSc, supporting its continued evaluation.Funding Statement Novartis Pharma AG, Basel, Switzerland.Abstract OC.56 Table 1Summary of preliminar…